Showing results (1921-1930 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 28, 2012
Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agentSang Joon Shin, Jee Won Hwang, Joong Bae Ahn, et al.
Investigational New Drugs|April 28, 2012
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcomaChristopher W Ryan, Chacon Matias, Mark Agulnik, et al.
Investigational New Drugs|May 8, 2012
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancerKeun Seok Lee, In Hae Park, Byung-Ho Nam, et al.
Investigational New Drugs|May 25, 2012
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinasesTeresa G Granda, David Cebrián, Sonia Martínez, et al.
Investigational New Drugs|May 23, 2012
Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancerNilesh A Patankar, Dawn Waterhouse, Dita Strutt, et al.
Investigational New Drugs|March 21, 2016
The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cellsFrancesca De Iuliis, Ludovica Taglieri, Gerardo Salerno, et al.
Investigational New Drugs|May 19, 2016
In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118Eduardo J Salustiano, Matheus L Dumas, Gabriel G Silva-Santos, et al.
Investigational New Drugs|April 4, 2016
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumorsB Milojkovic Kerklaan, S Slater, M Flynn, et al.
Investigational New Drugs|May 28, 2016
Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factorsNoura Benslama, Julien Bollard, Cécile Vercherat, et al.
Investigational New Drugs|May 15, 2016
The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell lineRaffaele Pezzani, Beatrice Rubin, Loris Bertazza, et al.
Pageof 372